18 May 2026
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18-59 at increased risk · First RSV vaccine approved for adults aged 18-59 years at increased…
18 May 2026 Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension Approval based on BaxHTN Phase…
14 May 2026
Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III…
12 March 2026
Halma plc Trading update 12 March 2026 Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for…
9 March 2026
GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and…
17 December 2025
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma · Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients…
16 December 2025
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps · First and only ultra-long-acting biologic with…
16 December 2025 Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus Convenient subcutaneous option has potential to reach…